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Recent publications have alerted clinicians to a syndrome of uveitic transilluminating iris depigmentation associated
with systemic fluoroquinolones and other antibiotics. Bilateral acute iris transillumination, which is associated with
loss of the iris pigment epithelium and results in iris transillumination, differs from the previously described bilateral
acute depigmentation of the iris, which is associated with atrophy of the iris stroma without transillumination. We
present a case of fluoroquinolone-associated uveitis with anterior segment optical coherence tomography imaging
to highlight some observations about this syndrome. We interpret pharmacokinetic data to help explain why oral,
but not topical, moxifloxacin may cause fluoroquinolone-associated uveitis.
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Recent publications have alerted clinicians to a syn-
drome of transilluminating iris depigmentation asso-
ciated with the use of systemic fluoroquinolones and
other antibiotics [1,2]. This syndrome, termed bilateral
acute iris transillumination by some authors [1], differs
from the previously described bilateral acute depigmen-
tation of the iris, which causes reversible atrophy of the
iris stroma without iris transillumination [3]. In contrast,
fluoroquinolone-associated uveitis preferentially targets
the iris pigment epithelium, leading to irreversible iris
transillumination [2].
We present a case of fluoroquinolone-associated uveitis
with anterior segment optical coherence tomography
(OCT) imaging to highlight some observations about this
syndrome. We interpret pharmacokinetic data to help ex-
plain why oral, but not topical, moxifloxacin may cause
fluoroquinolone-associated uveitis. We also discuss the
possible impact of the presence of the native crystalline
lens. Finally, we note that the anterior segment OCT find-
ings suggest that both the iris stroma and iris pigment epi-
thelium are affected in fluoroquinolone-associated uveitis.* Correspondence: robknape@gmail.com
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A 70-year-old Caucasian man complained of blurry vi-
sion and photophobia in both eyes for 2 weeks. His past
medical history was notable for lung cancer and an epi-
sode of pneumonia treated with oral moxifloxacin 3 days
before the ocular symptoms began. His visual acuity was
20/30 OD and 20/40 OS with intraocular pressures
(IOP) of 35 mmHg in both eyes. He had mild corneal
edema and symmetric 3+ anterior chamber pigmented
cells (Figure 1A,B). Gonioscopy revealed dense pigment
obscuring all angle structures (Figure 1C,D). The poster-
ior segments were normal. Serum laboratory evaluation
and polymerase chain reaction of the right eye aqueous
humor were negative for HSV, VZV, and CMV. He was
treated with topical steroids and cycloplegic and IOP-
lowering medications with little change in vision, IOP, or
pupil size. Retroillumination images at presentation and
2 weeks later showed stable iris transillumination defects
(Figure 1E,F,G,H), suggesting an acute, self-limited in-
jury. Anterior segment OCT images of the iris demon-
strated thinning, concavity, and adherence to the lens
(Figure 2A,B). The patient died from respiratory failure
after his 2-week follow-up visit.Comment
Previous reports have noted fluoroquinolone-associated
uveitis only with systemic fluoroquinolones [1,2]. Phar-
macokinetic data may explain why topical administrationn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Clinical presentation of the anterior segment.
Pigmented cells in the anterior chamber with deposition of a
pigmented ‘wreath’ on the corneal endothelium adjacent to the
limbus are seen in the right (A) and left (B) eyes. Gonioscopy shows
pigment anterior to Schwalbe's line and extending on to the
peripheral iris in the right (C) and left (D) eyes. Transillumination
defects noted at presentation in the right (E) and left (F) eyes were
stable 2 weeks later in the right (G) and left (H) eyes.
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After topical administration, there is a greater-than-
tenfold higher concentration of moxifloxacin in aqueous
(2.28 ± 1.23 μg/mL) than in vitreous (0.11 ± 0.05 μg/mL)
[4], whereas oral administration produces similar aque-
ous (1.34 ± 0.66 μg/mL) and vitreous concentrations
(1.58 ± 0.80 μg/mL) [5]. The steady serum and vitreous
reservoirs of moxifloxacin during oral administration
may maintain drug levels in the tissue at risk better than
intermittent topical therapy.
The lens status of affected patients may also be rele-
vant. To our knowledge, only phakic patients have been
reported with fluoroquinolone-associated uveitis [1,2].
Less drug diffuses posteriorly in phakic eyes [6], and
posterior-to-anterior clearance may also be impaired in
phakic eyes. Trapping of drug in the posterior chamber
by synechiae between an intact lens and the iris, as
demonstrated in our OCT (Figure 2), may result in
higher drug concentrations adjacent to the posterior
layers of the iris.
Why is intravitreal moxifloxacin injection apparently
safe [7]? Experience gained from cidofovir-induced uve-
itis and hypotony indicates that toxicity to the nonpig-
mented epithelium of the ciliary body is uncommon
after intravitreal therapy [8] compared to systemic ad-
ministration [9], an effect that may be due to the more
rapid clearance of intravitreally administered drug com-
pared to recirculation from a serum depot. Additionally,
in vitro toxicity studies have not examined the effect
on the iris pigment epithelium [10], which may have
different susceptibility to moxifloxacin toxicity. Finally,
greater light exposure of the iris may have a bearing on
the achieved toxicity.
Clinicians confronted with patients with acute onset of
uveitis and pigment dispersion should be aware of the
association between systemic fluoroquinolones and uve-
itis. Treatment with corticosteroids for prolonged pig-
ment dispersion after the initial inflammatory phase is
likely unnecessary and may contribute to glaucoma in
steroid responders. Intraocular pressure would be pre-
dicted to improve as the load of pigment in the trabecu-
lar meshwork subsides.
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Figure 2 OCT of the anterior segment. The right (A) and left (B) eyes show significant stromal thinning with iris concavity and posterior
synechiae.
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